Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
Vicente Escudero-VilaplanaRoberto Collado-BorrellJavier De CastroAmelia InsaAlex MartínezElena FernándezIvana SullivanAndrés FloresNatalia ArrabalDavid CarcedoAlba ManzanequePublished in: Journal of medical economics (2023)
Our results showed that adjuvant treatment with atezolizumab in patients with early-stage resected NSCLC with overexpression of PD-L1 and without EGFR and ALK mutations is cost-effective versus BSC as the ICERs and ICURs obtained are below the cost-effectiveness thresholds commonly considered in Spain, thus offering a new treatment alternative for these patients.
Keyphrases
- early stage
- small cell lung cancer
- end stage renal disease
- cell proliferation
- transcription factor
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- lymph node
- squamous cell carcinoma
- tyrosine kinase
- sentinel lymph node
- peritoneal dialysis
- replacement therapy
- locally advanced
- rectal cancer
- liver metastases